These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

327 related items for PubMed ID: 33524443

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Measurable residual disease monitoring in acute myeloid leukemia with t(8;21)(q22;q22.1): results from the AML Study Group.
    Rücker FG, Agrawal M, Corbacioglu A, Weber D, Kapp-Schwoerer S, Gaidzik VI, Jahn N, Schroeder T, Wattad M, Lübbert M, Koller E, Kindler T, Götze K, Ringhoffer M, Westermann J, Fiedler W, Horst HA, Greil R, Schroers R, Mayer K, Heinicke T, Krauter J, Schlenk RF, Thol F, Heuser M, Ganser A, Bullinger L, Paschka P, Döhner H, Döhner K.
    Blood; 2019 Nov 07; 134(19):1608-1618. PubMed ID: 31554635
    [Abstract] [Full Text] [Related]

  • 3. Significance of minimal residual disease monitoring by real-time quantitative polymerase chain reaction in core binding factor acute myeloid leukemia for transplantation outcomes.
    Yalniz FF, Patel KP, Bashir Q, Marin D, Ahmed S, Alousi AM, Chen J, Ciurea SO, Rezvani K, Popat UR, Shpall EJ, Champlin RE, Oran B.
    Cancer; 2020 May 15; 126(10):2183-2192. PubMed ID: 32101640
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Clinical significance of minimal residual disease in patients with t(8;21) acute myeloid leukemia in Japan.
    Narimatsu H, Iino M, Ichihashi T, Yokozawa T, Hayakawa M, Kiyoi H, Takeo T, Sawamoto A, Iida H, Tsuzuki M, Yanada M, Naoe T, Suzuki R, Sugiura I.
    Int J Hematol; 2008 Sep 15; 88(2):154-158. PubMed ID: 18553224
    [Abstract] [Full Text] [Related]

  • 6. The dynamics of RUNX1-RUNX1T1 transcript levels after allogeneic hematopoietic stem cell transplantation predict relapse in patients with t(8;21) acute myeloid leukemia.
    Qin YZ, Wang Y, Xu LP, Zhang XH, Chen H, Han W, Chen YH, Wang FR, Wang JZ, Chen Y, Mo XD, Zhao XS, Chang YJ, Liu KY, Huang XJ.
    J Hematol Oncol; 2017 Feb 06; 10(1):44. PubMed ID: 28166825
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. High aldehyde dehydrogenase activity at diagnosis predicts relapse in patients with t(8;21) acute myeloid leukemia.
    Yang L, Chen WM, Dao FT, Zhang YH, Wang YZ, Chang Y, Liu YR, Jiang Q, Zhang XH, Liu KY, Huang XJ, Qin YZ.
    Cancer Med; 2019 Sep 06; 8(12):5459-5467. PubMed ID: 31364309
    [Abstract] [Full Text] [Related]

  • 10. [Prognostic value of dynamic monitoring of RUNX1-RUNX1T1 transcript in pediatric acute myeloid leukemia].
    Gao HT, Zhang Y, Sun K, Guo JM, Chen YQ, Chen XL, Shi J, Niu XN, Wang F, Huo L.
    Zhonghua Xue Ye Xue Za Zhi; 2017 Mar 14; 38(3):210-215. PubMed ID: 28395444
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. RNA sequencing as an alternative tool for detecting measurable residual disease in core-binding factor acute myeloid leukemia.
    Kim T, Moon JH, Ahn JS, Ahn SY, Jung SH, Yang DH, Lee JJ, Shin MG, Choi SH, Lee JY, Tyndel MS, Lee HY, Kim KH, Cai Y, Lee YJ, Sohn SK, Min YH, Cheong JW, Kim HJ, Zhang Z, Kim DDH.
    Sci Rep; 2020 Nov 18; 10(1):20119. PubMed ID: 33208771
    [Abstract] [Full Text] [Related]

  • 13. Prognostic Role of Postinduction Minimal Residual Disease and Myeloid Sarcoma Type Extramedullary Involvement in Pediatric RUNX1-RUNX1T1 (+) Acute Myeloid Leukemia.
    Lee JW, Kim S, Jang PS, Chung NG, Cho B, Im SA, Kim M.
    J Pediatr Hematol Oncol; 2020 Apr 18; 42(3):e132-e139. PubMed ID: 31688618
    [Abstract] [Full Text] [Related]

  • 14. Role of minimal residual disease in the management of acute myeloid leukemia-a case-based discussion.
    Coltoff A, Houldsworth J, Keyzner A, Renteria AS, Mascarenhas J.
    Ann Hematol; 2018 Jul 18; 97(7):1155-1167. PubMed ID: 29704019
    [Abstract] [Full Text] [Related]

  • 15. Minimal residual disease monitoring in t(8;21) acute myeloid leukemia based on RUNX1-RUNX1T1 fusion quantification on genomic DNA.
    Duployez N, Nibourel O, Marceau-Renaut A, Willekens C, Helevaut N, Caillault A, Villenet C, Celli-Lebras K, Boissel N, Jourdan E, Dombret H, Figeac M, Preudhomme C, Renneville A.
    Am J Hematol; 2014 Jun 18; 89(6):610-5. PubMed ID: 24616160
    [Abstract] [Full Text] [Related]

  • 16. Core binding factor acute myeloid leukemia: the impact of age, leukocyte count, molecular findings, and minimal residual disease.
    Hoyos M, Nomdedeu JF, Esteve J, Duarte R, Ribera JM, Llorente A, Escoda L, Bueno J, Tormo M, Gallardo D, de Llano MPQ, Martí JM, Aventín A, Mangues R, Brunet S, Sierra J.
    Eur J Haematol; 2013 Sep 18; 91(3):209-218. PubMed ID: 23646898
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. In adults with t(8;21)AML, posttransplant RUNX1/RUNX1T1-based MRD monitoring, rather than c-KIT mutations, allows further risk stratification.
    Wang Y, Wu DP, Liu QF, Qin YZ, Wang JB, Xu LP, Liu YR, Zhu HH, Chen J, Dai M, Huang XJ.
    Blood; 2014 Sep 18; 124(12):1880-6. PubMed ID: 25082877
    [Abstract] [Full Text] [Related]

  • 19. Measurable Residual Disease at Induction Redefines Partial Response in Acute Myeloid Leukemia and Stratifies Outcomes in Patients at Standard Risk Without NPM1 Mutations.
    Freeman SD, Hills RK, Virgo P, Khan N, Couzens S, Dillon R, Gilkes A, Upton L, Nielsen OJ, Cavenagh JD, Jones G, Khwaja A, Cahalin P, Thomas I, Grimwade D, Burnett AK, Russell NH.
    J Clin Oncol; 2018 May 20; 36(15):1486-1497. PubMed ID: 29601212
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.